Update from the RESECT Study

With 17,500 patient records procured and 3,100 surgeons (and counting) involved, RESECT has already shown that there is significant global variation in the quality and outcomes of transurethral resection of bladder tumour (TURBT) surgery.

Fri, 28 Jul 2023 • Dr. Fortis Gaba, Albany Medical Center Albany (US)
Bladder CancerTURBTRESECTNon Muscle Invasive Bladder Cancer NMIBC
Co-Study Lead Kevin Gallagher discussing achievements of RESECT at EAU23

RESECT is an international multicentre observational study of TURBT surgery with randomised feedback to sites. The aim is to measure global achievement of TURBT quality indicators (QI) and to determine if audit and feedback can improve performance.

Can we significantly reduce the recurrence of non-muscle invasive bladder cancer after TURBT by dynamically auditing and comparing our practice to our peers? If so, the absolute impact could be monumental.

Study progress
221 hospitals from across the world were randomised in the prospective phase wherein half received interactive online performance feedback and an educational dashboard. The prospective data deadline is the end of June 2023. The study aims to report in early 2024.

Data presented at major conferences in 2022 and 2023 (EAU, BAUS, AUA, and USANZ) has demonstrated that there is significant variation in performance and variation in early recurrence rates regarding TURBT surgery between sites that could not be explained by currently understood tumour features. What is causing this variation? Can we reduce it? Watch this space.

RESECT collaborators meeting at EAU23
Around 30 of our global collaborators convened at EAU23 in picturesque Milan to catch up, dine together, and brainstorm to plan the final stages and analysis of the study. The discussions were enjoyable and comprised lively debates. There were presentations about local practice from some of our top European collaborators, Dr. Pietro Piazza (IT); Dr. Bernardo Teixeira (PT) and Dr. Loic Baekelandt (NL). Certificates were presented to the top recruiters, who are namely Dr. Piazza, Dr. Gautier Marcq (FR), Dr. Francesco Del Giudice (IT), and Dr. Luca Orecchia (IT).

A sincere “thank you” goes to all 1,300 of our global collaborators for their tireless efforts and dedication in improving the quality of this crucial core urological operation.

For more information
To help you complete the last phase of the study, please visit the website, which includes extensive resources. If you have any questions, you can reach us via email.